Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today ...

Dialysis may improve outcomes in patients suffering from treatment-resistant congestive heart failure (CHF) accompanied by severe renal insufficiency, new findings suggest. Trijntje T. Cnossen, MD, ...

The researchers of a recent British Medical Journal paper reviewed heart failure diagnosis and management data. Heart failure has led to considerable health and financial burdens globally, especially ...

Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with symptomatic ...

The American College of Cardiology, the American Heart Association and the Heart Failure Society of America released new guidelines Friday that add a fourth class of medication to the recommended ...

Heart Failure Awareness Week (HFAW), which takes place February 11-17 2024, was created to encourage education and awareness on heart failure and best practices for prevention.¹ While the entirety of ...

Approximately 6.7 million Americans over the age of 20 currently live with heart failure, with this number projected to rise to 8.5 million by 2030. The lifetime risk of developing heart failure has ...

Congestive heart failure is a chronic condition in which the heart is unable to pump blood efficiently. This is often caused as a result of prolonged cardiovascular conditions that impair the heart’s ...